Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda

Objective: To model the effects of antiretroviral therapy (ART) and HIV vaccines on HIV transmission using empirical data from studies in Rakai, Uganda. Design: A stochastic simulation model estimated HIV incidence, probabilities of transmission per coital act and the reproductive number (R0) with ART and HIV vaccines. Model inputs included Rakai data on HIV transmission probabilities per coital act by HIV viral load, age and gender, and sexual behaviors. The impacts of therapy were derived from US programs, and vaccine assumptions included preventive efficacies ranging from 25 to 75%. Component projection models estimated the numbers of HIV-infected persons over 20 years. Results: The model incidence [1.57/100 person years (PY)] closely fitted empirical data (1.5/100 PY). Simulations of ART using DHHS treatment guidelines, predicted declines in HIV incidence, but R0 remained > 1.0, and the numbers of HIV-positive persons did not change substantially over 20 years. Preventive vaccines with > 50% efficacy and > 50% population coverage could reduce R0 to < 1.0, and substantially reduce the number of HIV-infected persons over 20 years. Concurrent ART and a preventive vaccine can have substantial impact at lower levels of population coverage and would markedly reduce the HIV infected population over 20 years. However, behavioral disinhibition with increased numbers of sexual partners in either ART or vaccine recipients, increased HIV incidence and diminished intervention impact. Conclusion: ART alone cannot control the HIV epidemic in mature epidemics such as Rakai, and persons in need of therapy will increase over time. ART in combination with a low efficacy vaccine could control the epidemic, if behavioral disinhibition is prevented.

[1]  Steven Gibson,et al.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. , 2002, American journal of public health.

[2]  H. Binswanger Public health. HIV/AIDS treatment for millions. , 2001, Science.

[3]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[4]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[5]  Debashis Kushary,et al.  Bootstrap Methods and Their Application , 2000, Technometrics.

[6]  H. P. Binswanger HIV/AIDS Treatment for Millions , 2001, Science.

[7]  Maureen Miller,et al.  Sexual behavior changes and protease inhibitor therapy , 2000 .

[8]  R. Anderson,et al.  Low-efficacy HIV vaccines: potential for community-based intervention programmes , 1996, The Lancet.

[9]  S. Long,et al.  Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998 , 1998, The Lancet.

[10]  C. Yoder,et al.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression , 2000, AIDS.

[11]  H. Gershengorn,et al.  A tale of two futures: HIV and antiretroviral therapy in San Francisco. , 2000, Science.

[12]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.

[13]  G. Garnett,et al.  An introduction to mathematical models in sexually transmitted disease epidemiology , 2002, Sexually transmitted infections.

[14]  W. Spaan,et al.  Access to treatment for HIV in developing countries , 1999, The Lancet.

[15]  J. Esparza,et al.  Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? , 2000, The Lancet.

[16]  R. Selik,et al.  Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. , 2001, JAMA.

[17]  R. Hogg,et al.  Models of survival in HIV infection and their use in the quantification of treatment benefits. , 1998, American journal of epidemiology.

[18]  S. Holmberg,et al.  Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy. , 1999, AIDS.

[19]  Ronald H Gray,et al.  Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial , 1999, The Lancet.

[20]  Joseph Feldman,et al.  The Women's Interagency HIV Study , 1998 .

[21]  R. Moore,et al.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[22]  Noah Kiwanuka,et al.  Mortality associated with HIV infection in rural Rakai District, Uganda , 2000, AIDS.

[23]  HOMAS,et al.  VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 , 2000 .

[24]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[25]  Arriaga Ee,et al.  Population analysis with microcomputers. , 1994 .

[26]  S. Kippax,et al.  Modelling the effect of combination antiretroviral treatments on HIV incidence , 2001, AIDS.

[27]  Thomas C. Quinn,et al.  A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda , 1998, AIDS.

[28]  Providing antiretroviral therapy for HIV infection. , 2001, The New England journal of medicine.

[29]  Anthony C. Davison,et al.  Bootstrap Methods and Their Application , 1998 .

[30]  C. Mahé,et al.  HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? , 2002, AIDS.

[31]  J. Gallant,et al.  Strategies for long-term success in the treatment of HIV infection. , 2000, JAMA.

[32]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.